130 related articles for article (PubMed ID: 38376298)
41. Genetic Polymorphisms of the Human Cytochrome P450 1A1 (CYP1A1) and Cervical Cancer Susceptibility among Northeast Thai Women.
Wongpratate M; Ishida W; Phuthong S; Natphopsuk S; Ishida T
Asian Pac J Cancer Prev; 2020 Jan; 21(1):243-248. PubMed ID: 31983191
[TBL] [Abstract][Full Text] [Related]
42. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population.
Bozina N; Granić P; Lalić Z; Tramisak I; Lovrić M; Stavljenić-Rukavina A
Croat Med J; 2003 Aug; 44(4):425-8. PubMed ID: 12950145
[TBL] [Abstract][Full Text] [Related]
43. Effect of genetic polymorphisms on the pharmacokinetics of gefitinib in healthy Chinese volunteers.
Chen YR; Yu X; Xu LM; Mei J; Tian ML; Xu M; Jin QY; Ye LB; Yang SX
Xenobiotica; 2024 Jan; 54(1):38-44. PubMed ID: 38085693
[TBL] [Abstract][Full Text] [Related]
44. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
[TBL] [Abstract][Full Text] [Related]
45. Understanding Role of DNA Repair and Cytochrome p-450 Gene Polymorphisms in Cervical Cancer Patient Treated With Concomitant Chemoradiation.
Abbas M; Kushwaha VS; Srivastava K; Banerjee M
Br J Biomed Sci; 2022; 79():10120. PubMed ID: 35996502
[No Abstract] [Full Text] [Related]
46. Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations.
Zuo J; Xia D; Jia L; Guo T
Pharmazie; 2012 Jul; 67(7):639-44. PubMed ID: 22888523
[TBL] [Abstract][Full Text] [Related]
47. Genetic Polymorphism of Drug-Metabolizing Enzymes CYP2C9 and CYP2C19 in Moroccan Population.
Afilal D; Basselam MA; Brakez Z; Chouham S; Brehm A; Izaabel EH
Genet Test Mol Biomarkers; 2017 May; 21(5):298-304. PubMed ID: 28282224
[TBL] [Abstract][Full Text] [Related]
48. Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH-cytochrome P450 reductase.
Fujita K; Nakayama K; Yamazaki Y; Tsuruma K; Yamada M; Nohmi T; Kamataki T
Environ Mol Mutagen; 2001; 38(4):329-38. PubMed ID: 11774365
[TBL] [Abstract][Full Text] [Related]
49. Dose regimens for Chinese adult liver transplant recipients according to the genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in recipients and donors.
Zhu L; Liao S; Wang N; Ge T; Yang J; Xu G; Wang J; Li K; Li G
Int J Clin Pharmacol Ther; 2016 Aug; 54(8):587-96. PubMed ID: 27191765
[TBL] [Abstract][Full Text] [Related]
50. Possible role of CYP2C9 & CYP2C19 single nucleotide polymorphisms in drug refractory epilepsy.
Lakhan R; Kumari R; Singh K; Kalita J; Misra UK; Mittal B
Indian J Med Res; 2011 Sep; 134(3):295-301. PubMed ID: 21985811
[TBL] [Abstract][Full Text] [Related]
51. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting.
Gökalp O; Gunes A; Cam H; Cure E; Aydın O; Tamer MN; Scordo MG; Dahl ML
Eur J Clin Pharmacol; 2011 Dec; 67(12):1223-9. PubMed ID: 21691805
[TBL] [Abstract][Full Text] [Related]
52. Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations.
Lasker JM; Wester MR; Aramsombatdee E; Raucy JL
Arch Biochem Biophys; 1998 May; 353(1):16-28. PubMed ID: 9578596
[TBL] [Abstract][Full Text] [Related]
53. Polymorphisms and haplotypes of TLR4, TLR9 and CYP1A1 genes possibly interfere with high-risk human papillomavirus infection and cervical cancer susceptibility in Jharkhand, India.
Nath N; Mishra P; Panda AK; Mishra R
Int Immunopharmacol; 2020 Nov; 88():106925. PubMed ID: 32871478
[TBL] [Abstract][Full Text] [Related]
54. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
Fu M; Luo L; Feng S; Lin H; Lu Z; Gu F; Fan Y; Wu B; Huang J; Shen K
Br J Clin Pharmacol; 2023 Dec; 89(12):3659-3668. PubMed ID: 37464978
[TBL] [Abstract][Full Text] [Related]
55. Significant association between CYP1A1 T3801C polymorphism and cervical neoplasia risk: a systematic review and meta-analysis.
Xia L; Gao J; Liu Y; Wu K
Tumour Biol; 2013 Feb; 34(1):223-30. PubMed ID: 23055196
[TBL] [Abstract][Full Text] [Related]
56. Genetic variations in the xenobiotic-metabolizing enzymes CYP1A1, CYP1A2, CYP2C9, CYP2C19 and susceptibility to colorectal cancer among Turkish people.
Özhan G; Mutur M; Ercan G; Alpertunga B
Genet Test Mol Biomarkers; 2014 Apr; 18(4):223-8. PubMed ID: 24527758
[TBL] [Abstract][Full Text] [Related]
57. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.
Chang TK; Yu L; Goldstein JA; Waxman DJ
Pharmacogenetics; 1997 Jun; 7(3):211-21. PubMed ID: 9241661
[TBL] [Abstract][Full Text] [Related]
58. Association of CYP1A1 T3801C (rs4646903) variant with the susceptibility and progression of B-chronic lymphocytic Leukemia (B-CLL) in the Egyptian population.
Al-Adl M; El-Said A; El-Sebaie A; Refaat S; Youssef MM
Gene; 2023 Oct; 883():147673. PubMed ID: 37506988
[TBL] [Abstract][Full Text] [Related]
59. Effect of Chronic Kidney Disease on Nonrenal Elimination Pathways: A Systematic Assessment of CYP1A2, CYP2C8, CYP2C9, CYP2C19, and OATP.
Tan ML; Yoshida K; Zhao P; Zhang L; Nolin TD; Piquette-Miller M; Galetin A; Huang SM
Clin Pharmacol Ther; 2018 May; 103(5):854-867. PubMed ID: 28990182
[TBL] [Abstract][Full Text] [Related]
60. Assessment of the association of
Barek MA; Basher MA; Aziz MA; Hossen MS; Jahan N; Afroz N; Begum M; Jafrin S; Uddin MS; Millat MS; Hoque MM; Islam MS
Heliyon; 2023 Jul; 9(7):e17712. PubMed ID: 37483787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
